Photo: Depositphotos
Aug 5, 2025, 11:47
Sergio Cifuentes Canaval: Comparative Table of Pembrolizumab Trials in HCC
Sergio Cifuentes Canaval, Medical Oncologist, ASCO International Development and Education Award (IDEA) Recipient – 2025 at Conquer Cancer, the ASCO Foundation, shared a post on X:
“Comparative Table of Pembrolizumab Trials in HCC
Key Takeaways
Only KEYNOTE-224 (Phase II) met its primary endpoint (ORR), but with low clinical impact (ORR 16%).
Both phase III trials (KEYNOTE-240, LEAP-002) failed their primary OS endpoints despite:
- Nominal OS improvements (HR <1)
- Higher ORR in combo arm (LEAP-002)
Context vs. Competitors:
- Atezo+Bev (IMbrave150): Positive OS (HR 0.66, p<0.001)
- Tremeli+Durva (HIMALAYA): Positive OS (HR 0.78, p=0.003)
Conclusion:
Pembro-based regimens consistently underdelivered in HCC pivotal trials, failing to demonstrate statistically significant survival benefits in phase III settings.”
More posts featuring Sergio Cifuentes Canaval.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 5, 2025, 11:41
Aug 5, 2025, 11:31
Aug 5, 2025, 11:29
Aug 5, 2025, 11:18
Aug 5, 2025, 10:09
Aug 5, 2025, 10:08
Aug 5, 2025, 10:05